
Molekularne diagnostične preiskave in vitro - Specifikacije za predpreiskovalne procese za cirkulirajoče tumorske celice (CTC) v venski polni krvi - 1. del: Izolirani RNK

Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for circulating tumor cells (CTCs) in venous whole blood - Part 1: Isolated RNA

Molekularanalytische in-vitro-diagnostische Verfahren - Spezifikationen für präanalytische Prozesse für zirkulierende Tumorzellen (CTC) in venösen Vollblutproben - Teil 1: Isolierte RNA

Ta slovenski standard je istoveten z: FprCEN/TS 17390-1

ICS:

11.100.10	Diagnostični preskusni sistemi in vitro	In vitro diagnostic test systems
-----------	---	----------------------------------

kSIST-TS FprCEN/TS 17390-1:2019	en,fr,de
--	-----------------

ITeH STANDARD PREVIEW
(standards.iteh.ai)

Full standard:
<https://standards.iteh.ai/catalog/standards/sist/12139892-be47-4111-9641-e458f2e14991/ksist-ts-fprcen-ts-17390-1-2019>

TECHNICAL SPECIFICATION
SPÉCIFICATION TECHNIQUE
TECHNISCHE SPEZIFIKATION

FINAL DRAFT
FprCEN/TS 17390-1

July 2019

ICS 11.100.10

English Version

Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for circulating tumor cells (CTCs) in venous whole blood - Part 1: Isolated RNA

Molekularanalytische in-vitro-diagnostische Verfahren
- Spezifikationen für präanalytische Prozesse für
zirkulierende Tumorzellen (CTC) in venösen
Vollblutproben - Teil 1: Isolierte RNA

This draft Technical Specification is submitted to CEN members for Vote. It has been drawn up by the Technical Committee CEN/TC 140.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.

Recipients of this draft are invited to submit, with their comments, notification of any relevant patent rights of which they are aware and to provide supporting documentation.

Warning : This document is not a Technical Specification. It is distributed for review and comments. It is subject to change without notice and shall not be referred to as a Technical Specification.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

Contents

Page

European foreword.....	3
Introduction	4
1 Scope.....	5
2 Normative references.....	5
3 Terms and definitions	5
4 General considerations.....	10
5 Outside the laboratory	11
5.1 Specimen collection.....	11
5.1.1 Information about the specimen donor/patient	11
5.1.2 Selection of the venous whole blood collection tube by the laboratory	11
5.1.3 Venous whole blood specimen collection from the donor/patient and stabilization procedures.....	12
5.1.4 Information on the specimen and storage requirements at the blood collection facility.....	12
5.2 Transport requirements.....	13
5.2.1 General.....	13
5.2.2 Using blood collection tubes with stabilizers	13
5.2.3 Using blood collection tubes without stabilizers.....	13
6 Inside the laboratory	14
6.1 Specimen reception.....	14
6.2 Storage requirements for the venous whole blood specimen	14
6.3 Enrichment of CTCs	14
6.3.1 General.....	14
6.3.2 Using a commercial CTC enrichment system	14
6.3.3 Using laboratory's own CTC enrichment protocols	15
6.4 Quality of enriched CTCs.....	15
6.5 Storage of enriched CTCs.....	15
6.6 Isolation of CTCs	15
6.6.1 General.....	15
6.6.2 Using a commercial CTC isolation system.....	16
6.6.3 Using the laboratory's own CTC isolation procedure	16
6.7 Processing of isolated CTCs	16
6.8 Isolation of RNA from an enriched CTC sample.....	17
6.8.1 General.....	17
6.8.2 Using a commercial RNA isolation kit.....	17
6.8.3 Using the laboratory's own RNA isolation procedure.....	17
6.9 Quantity and quality assessment of isolated RNA from enriched or isolated CTCs	18
6.10 Storage of isolated RNA from enriched CTCs	18
6.10.1 General.....	18
6.10.2 RNA isolated with a commercially available kit	19
6.10.3 RNA isolated with the laboratory's own protocols	19
Annex A (informative) Decision guideline for critical steps of the CTC pre-analytical workflow for RNA isolation	20
Bibliography.....	23

European foreword

This document (FprCEN/TS 17390-1:2019) has been prepared by Technical Committee CEN/TC 140 “In vitro diagnostic medical devices”, the secretariat of which is held by DIN.

This document is currently submitted to the Vote on TS.

CEN/TS 17390 consists of the following parts, under the general title *Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for Circulating Tumor Cells (CTCs) in whole blood*:

- Part 1: *Isolated RNA*
- Part 2: *Isolated DNA*
- Part 3: *Preparations for analytical CTC staining*

ITEH STANDARD PREVIEW
(standards.iteh.ai)
Full standard:
<https://standards.iteh.ai/catalog/standards/sist/12139882-be47-4111-9641-e458f2e14991/k SIST-TS-FprCEN-TS-17390-1-2019>

FprCEN/TS 17390-1:2019 (E)

Introduction

Solid tumours release cells and bioanalytes into blood and other body fluids. This has opened the option of minimally-invasive tumour detection, diagnosis and characterization from venous whole blood (liquid biopsies). Liquid biopsies are expected to enable earlier detection and diagnosis of cancers and advance personalized patient treatment. These applications have become one of the fastest growing segments of the entire diagnostic market.

Circulating tumour cells (CTCs) in venous whole blood reflect the disease complexity that evolves during tumour progression, with distinct genetic, epigenetic and expression features. Besides the prognostic role of CTC identification and/or enumeration in cancer progression, CTC molecular characterization can improve e.g. disease outcome prediction, therapeutic guidance and post-treatment monitoring of the patient.

CTCs are now considered as a surrogate of tumour tissue in cancer early development, progression and metastatic phase.

Molecular characterization of CTCs can provide for example a strategy for monitoring cancer genotypes during systemic therapies [1], identification of mechanisms of disease progression, identification of novel targets for treatment [2] and to select targeted therapies. Moreover, CTC single-cell sequencing is emerging as an important tool for tumour genomic heterogeneity analysis [3] [4] [5].

CTCs are fragile and tend to degrade within a few hours when collected in conventional blood collection tubes, e.g. EDTA containing tubes, without dedicated CTC stabilizers. They are extremely rare, especially in early disease, e.g. less than 10 cells per 10 ml of blood, representing a ratio of approx. $1:10^7$ CTCs to white blood cells (WBCs). This low ratio represents a significant challenge to CTC enrichment required for examination.

RNA profiles of CTCs resemble gene expression profiles of tumours. For RNA profile analysis, measures need to be taken to get rid of the WBCs in order to obtain sufficiently enriched CTC specific RNA.

RNA profiles can change significantly after blood collection, during CTC enrichment and isolation. Therefore, special measures need to be taken to obtain good quality CTC samples and good quality isolated RNA for gene expression analysis [4] [6].

Consequently, standardization of all steps of the pre-examination process is required. This includes blood collection and stabilization, transport, storage, CTC enrichment, CTC isolation (if required), and RNA isolation. A decision guideline for the critical steps of the CTC pre-analytical workflow for RNA isolation is provided in Annex A.

This document describes special measures that need to be taken to obtain appropriate quality and quantity of RNA from CTC containing blood specimens for subsequent examination.

In this document, the following verbal forms are used:

- “shall” indicates a requirement;
- “should” indicates a recommendation;
- “may” indicates a permission;
- “can” indicates a possibility or a capability.

1 Scope

This document gives guidelines on the handling, storage, processing and documentation of human venous whole blood specimens intended for the examination of RNA isolated from circulating tumour cells (CTCs) during the pre-examination phase before a molecular examination is performed.

This document is applicable to molecular *in vitro* diagnostic examinations including laboratory developed tests performed by medical laboratories. It is also intended to be used by laboratory customers, *in vitro* diagnostics developers and manufacturers, biobanks, institutions and commercial organizations performing biomedical research, and regulatory authorities.

This document does not cover the isolation of cellular RNA directly from venous whole blood containing CTCs. This is covered in EN ISO 20186-1, *Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for venous whole blood - Part 1: Isolated cellular RNA*.

This document does not cover the isolation of specific white blood cells and subsequent isolation of cellular RNA therefrom.

This document does not cover pre-analytical workflow requirements for viable CTC cryopreservation and culturing.

NOTE 1 The requirements given in this document can also be applied to other circulating rare cells (e.g. fetal cells).

NOTE 2 International, national or regional regulations or requirements can also apply to specific topics covered in this document.

2 Normative references

The following documents, in whole or in part, are normatively referenced in this document and are indispensable for its application. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

EN ISO 15189:2012, *Medical laboratories - Requirements for quality and competence (ISO 15189:2012, Corrected version 2014-08-15)*

ISO 15190, *Medical laboratories — Requirements for safety*

3 Terms and definitions

For the purposes of this document, the terms and definitions given in EN ISO 15189 and the following terms and definitions apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- IEC Electropedia: available at <http://www.electropedia.org/>
- ISO Online browsing platform: available at <http://www.iso.org/obp>

3.1

aliquot

portion of a larger amount of homogenous material, assumed to be taken with negligible sampling error

Note 1 to entry: The term is usually applied to fluids. Tissues are heterogeneous and therefore cannot be aliquoted.

Note 2 to entry: The definition is derived from References [7], [8] and [9].

[SOURCE: EN ISO 20166-3:2018, 3.1]

FprCEN/TS 17390-1:2019 (E)**3.2****ambient temperature**

unregulated temperature of the surrounding air

[SOURCE: EN ISO 20166-3:2018, 3.2]

3.3**analyte**

component represented in the name of a measurable quantity

[SOURCE: EN ISO 17511:2003, 3.2, modified — EXAMPLE has been removed.]

3.4**analytical test performance**

accuracy, precision, specificity and sensitivity of a test to measure the analyte of interest

Note 1 to entry: Other test performance characteristics such as robustness, repeatability can apply as well.

[SOURCE: EN ISO 20184-1:2018, 3.4]

3.5**blood collection set**

intravenous device specialized for venipuncture consisting of a stainless steel bevelled needle and tube (tubing) with attached plastic wings and fitting connector

Note 1 to entry: The connector attaches to an additional blood collection device, e.g. a blood collection tube.

3.6**blood collection tube**

tube used for blood collection, usually in a vacuum which forces blood from the vein through the needle and into the tube

3.7**backflow**

flow of a liquid opposite to the usual or desired direction

3.8**circulating tumor cells****CTCs**

cells present in blood, originating from a primary and/or metastatic site of a tumor

3.9**CTC enrichment**

any method that is able to increase the ratio of CTCs to other cells

3.10**CTC isolation**

any method resulting in a sample containing CTCs without any other cell types

3.11**diagnosis**

identification of a disease from its signs and symptoms, where the diagnostic process can involve examinations and tests for classification of an individual's condition into separate and distinct categories or subclasses that allow medical decisions about treatment and prognosis to be made

[SOURCE: EN ISO 20184-1:2018, 3.6]

3.12**DNase****deoxyribonuclease**

enzyme that catalyzes the degradation of DNA into smaller components

[SOURCE: EN ISO 20186-1:2018, 3.11]

3.13**examination****analytical test**

set of operations having the object of determining the value or characteristics of a property

Note 1 to entry: Processes that start with the isolated analyte and include all kinds of parameter testing or chemical manipulation for quantitative or qualitative examination.

[SOURCE: EN ISO 15189:2012, 3.7, modified — Notes to entry 1 to 3 have been removed, Note 1 to entry has been added and “analytical test” has been added as a preferred term.]

3.14**examination performance****analytical test performance****analytical performance**

ability of an examination procedure to measure or detect a particular analyte

Note 1 to entry: Analytical performance is determined from analytical performance studies used to assess the ability of an *in vitro* diagnostic examination procedure to measure or detect a particular analyte.

Note 2 to entry: Analytical performance includes such characteristics as analytical sensitivity, detection limit, analytical specificity (interference and cross-reactivity), trueness, precision and linearity.

[SOURCE: ISO/TS 17822-1:2014, 3.2, modified — “analytical test performance” and “analytical performance” have been added as preferred terms.]

3.15**examination manufacturer****analytical test manufacturer**

group or company that provides the specific analytical test

3.16**needle holder**

barrel used in routine venipuncture procedures to hold the blood collection tube in place and to protect the phlebotomist from direct contact with blood

[SOURCE: EN ISO 20186-1:2018, 3.18]

FprCEN/TS 17390-1:2019 (E)**3.17****pre-examination processes****preanalytical phase****preanalytical workflow**

processes that start, in chronological order, from the clinician's request and include the examination request, preparation and identification of the patient, collection of the primary sample(s), transportation to and within the medical or pathology laboratory, isolation of analytes, and end when the analytical examination begins

Note 1 to entry: The pre-examination phase includes preparative processes that influence the outcome of the intended examination.

[SOURCE: EN ISO 15189:2012, 3.15, modified — “pre-analytical workflow” has been added as a preferred term, Note 1 to entry has been added and the definition has been extended.]

3.18**primary sample****specimen**

discrete portion of a body fluid, breath, hair or tissue taken for examination, study or analysis of one or more quantities or properties assumed to apply for the whole

[SOURCE: EN ISO 15189:2012, 3.16, modified — Notes to entry 1 to 3 have been removed.]

3.19**proficiency testing**

evaluation of participant performance against pre-established criteria by means of inter-laboratory comparisons

[SOURCE: ISO 17043:2010, 3.7, modified — Notes to entry 1 to 3 have been removed.]

3.20**RNA****ribonucleic acid**

polymer of ribonucleotides occurring in a double-stranded or single-stranded form

[SOURCE: EN ISO 22174:2005, 3.1.3]

3.21**RNA proficiency testing program**

proficiency testing for RNA based examinations

3.22**RNA profile**

amounts of different RNA molecules present in a specimen or sample, that can be measured in the absence of any losses, inhibition and interference

3.23**RNase****ribonuclease**

enzyme that catalyzes the degradation of RNA into smaller components

[SOURCE: EN ISO 20186-1:2018, 3.24]